These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 25875173)

  • 21. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
    Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
    Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global DNA methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment - A pilot study.
    Tsang JS; Vencken S; Sharaf O; Leen E; Kay EW; McNamara DA; Deasy J; Mulligan ED
    Eur J Surg Oncol; 2014 Nov; 40(11):1459-66. PubMed ID: 25108814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Helbling D; Bodoky G; Gautschi O; Sun H; Bosman F; Gloor B; Burkhard R; Winterhalder R; Madlung A; Rauch D; Saletti P; Widmer L; Borner M; Baertschi D; Yan P; Benhattar J; Leibundgut EO; Bougel S; Koeberle D
    Ann Oncol; 2013 Mar; 24(3):718-25. PubMed ID: 23139259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography for predicting pathologic response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Chennupati SK; Quon A; Kamaya A; Pai RK; La T; Krakow TE; Graves E; Koong AC; Chang DT
    Am J Clin Oncol; 2012 Aug; 35(4):334-9. PubMed ID: 21422989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
    Formica V; Benassi M; Del Vecchio Blanco G; Doldo E; Martano L; Portarena I; Nardecchia A; Lucchetti J; Morelli C; Giudice E; Rossi P; Anselmo A; Sileri P; Sica G; Orlandi A; Santoni R; Roselli M
    Med Oncol; 2018 May; 35(6):83. PubMed ID: 29721745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.
    Farkas R; Pozsgai E; Schally AV; Szigeti A; Szigeti E; Laszlo Z; Papp A; Gomori E; Mangel L; Horvath PO; Bellyei S
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):387-95. PubMed ID: 22160161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusion-weighted magnetic resonance imaging in monitoring rectal cancer response to neoadjuvant chemoradiotherapy.
    Barbaro B; Vitale R; Valentini V; Illuminati S; Vecchio FM; Rizzo G; Gambacorta MA; Coco C; Crucitti A; Persiani R; Sofo L; Bonomo L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):594-9. PubMed ID: 22099033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting Pathological Complete Regression with Haematological Markers During Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
    Lee JH; Song C; Kang SB; Lee HS; Lee KW; Kim JS
    Anticancer Res; 2018 Dec; 38(12):6905-6910. PubMed ID: 30504408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NPTX2 is associated with neoadjuvant therapy response in rectal cancer.
    Karagkounis G; Thai L; DeVecchio J; Gantt GA; Duraes L; Pai RK; Kalady MF
    J Surg Res; 2016 May; 202(1):112-7. PubMed ID: 27083956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Daniel ES; Gibbs P; Guerrieri M; Faragher I
    Colorectal Dis; 2014 Oct; 16(10):783-7. PubMed ID: 24786681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.
    Tomono A; Yamashita K; Kanemitsu K; Sumi Y; Yamamoto M; Kanaji S; Imanishi T; Nakamura T; Suzuki S; Tanaka K; Kakeji Y
    Int J Clin Oncol; 2016 Apr; 21(2):344-349. PubMed ID: 26338272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
    Greenbaum A; Martin DR; Bocklage T; Lee JH; Ness SA; Rajput A
    Clin Colorectal Cancer; 2019 Jun; 18(2):102-109. PubMed ID: 30935775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy.
    Huebner M; Wolff BG; Smyrk TC; Aakre J; Larson DW
    World J Surg; 2012 Mar; 36(3):675-83. PubMed ID: 22270980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of APAF-1 and COX-2 expression in pathologic complete response to neoadjuvant chemoradiotherapy for patients with locally advanced rectal adenocarcinoma.
    Peng H; You K; Zhang R; Xi S; Zhang T; Dong J; Cai M; Wang C; Zhang H; Zhou T; Gao Y; Wen B
    Oncotarget; 2016 Jun; 7(23):35233-40. PubMed ID: 27153549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer.
    Ippolito D; Drago SG; Pecorelli A; Maino C; Querques G; Mariani I; Franzesi CT; Sironi S
    World J Gastroenterol; 2020 May; 26(20):2657-2668. PubMed ID: 32523318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on the relationship between tumor regression grade and lymph node regression grade].
    Zhao Q; Fu C; Yu E; Zhang W; Meng R; Wang H; Hao L; Wang H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1050-1054. PubMed ID: 28900999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Best MRI predictors of complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.
    Sathyakumar K; Chandramohan A; Masih D; Jesudasan MR; Pulimood A; Eapen A
    Br J Radiol; 2016; 89(1060):20150328. PubMed ID: 26828967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.